Grant Award Details
Complete a Phase 1 clinical trial for malignant Glioma with autologous Chimeric Antigen Receptor engineered central memory T cells (CAR-Tcm).
Grant Application Details
- Phase I Study of Chimeric Antigen Receptor Engineered Central Memory T cells for the Treatment of Malignant Glioma
Therapeutic Candidate or Device
A promising immunotherapy utilizing a patient’s memory T cells engineered to express chimeric antigen receptors for targeted tumor killing.
Malignant glioma (WHO III and IV), including glioblastoma (WHO IV), that express the tumor-associated antigen IL-13 receptor alpha 2 (IL13Rα2).
A promising immunotherapy utilizing a patient’s memory T cells genetically engineered to express chimeric antigen receptors for targeted tumor killing. Upon adoptive transfer the CAR T cell product specifically recognizes and diretly destroys malignant glioma cell expressing IL13Rα2.
Unmet Medical Need
This proposal seeks to address the unmet medical need for more effective therapy against malignant glioma by engineering de novo antitumor immunity using patient-specific chimeric antigen receptor (CAR)-modified T cells.
Phase I trial completed
Major Proposed Activities
- Manufacture and clinically evaluate intraventricular versus dual intraventricular and intratumoral delivery of CAR T cells
- Evaluate safety, feasibility and preliminary evidence of efficacy across all routes of administration.
- Develop and establish reagents and methods for a Phase II clinical trial
This proposal aims to benefit the citizens of California by developing a more effective therapy against glioblastoma, one of the least curable human cancers. Further, this project will produce economic benefits through the creation and maintenance of skilled jobs, along with the purchasing of equipment and supplies from in-state companies. This project will also yield long-reaching benefit by establishing California as a leader in biomedical research both nationally and internationally.